Both treatments significantly lowered HOMA-IR; however, the decrease was similar between the groups (P = 0.724).<h4>Conclusions</h4>Pemafibrate is more effective than bezafibrate at reducing ALT levels while offering similar beneficial effects on insulin resistance and endothelial function in CAD patients with MASLD. Here, GPT is linked to Insulin resistance.